Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Stock analysts at Wedbush lowered their Q2 2025 EPS estimates for shares of Corbus Pharmaceuticals in a report issued on Tuesday, May 6th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will post earnings per share of ($1.03) for the quarter, down from their prior estimate of ($0.76). Wedbush currently has a “Outperform” rating and a $51.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. Wedbush also issued estimates for Corbus Pharmaceuticals’ Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($4.38) EPS, FY2026 earnings at ($4.02) EPS, FY2027 earnings at ($6.55) EPS and FY2028 earnings at ($5.28) EPS.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.13).
View Our Latest Stock Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Stock Performance
CRBP opened at $6.45 on Friday. The stock has a fifty day moving average of $6.33 and a 200-day moving average of $10.81. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $61.90. The company has a market capitalization of $78.90 million, a P/E ratio of -1.38 and a beta of 3.19.
Hedge Funds Weigh In On Corbus Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRBP. JPMorgan Chase & Co. lifted its holdings in Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,172 shares during the period. Charles Schwab Investment Management Inc. increased its position in Corbus Pharmaceuticals by 4.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 97,882 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 4,239 shares during the period. Geode Capital Management LLC raised its holdings in Corbus Pharmaceuticals by 5.5% during the 4th quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company’s stock worth $3,110,000 after purchasing an additional 13,773 shares during the last quarter. Altium Capital Management LLC lifted its position in shares of Corbus Pharmaceuticals by 97.4% in the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company’s stock worth $4,543,000 after purchasing an additional 190,000 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Corbus Pharmaceuticals by 769.4% in the 4th quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company’s stock valued at $1,641,000 after purchasing an additional 123,100 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
See Also
- Five stocks we like better than Corbus Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- Buy P&G Now, Before It Sets A New All-Time High
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- How to trade penny stocks: A step-by-step guide
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.